Cheaper, Effective Oral ‘Ozempic’ is On the Way!
The race is on to develop the first daily weight-loss pill that would be both cheaper and less invasive than the current injectable drugs on the market, with the latest strong trial results from US company Terns following similarly positive outcomes from competitors including Eli Lilly, Roche and Structure Therapeutics.
The one-a-day glucagon-like peptide-1 receptor (GLP-1R) agonist tablet would work much like the current suite of medications including Wegovy and Ozempic, (semaglutide) and Zepbound(tirzepatide), but would take away the need to self-inject the drug in order to achieve the same weight-loss results. These small-molecule drugs effectively target the gastrointestinal tract, doing away with the need to administer the medication by injection.
The latest results come from California’s Terns Pharmaceuticals, which has reported its findings following a 28-day Phase I clinical trial of its TERN-601 oral medication, testing for tolerability and safety.
Excerpted from News Atlas
